Theragenics Corporation

Analysis

Theragenics Corporation currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. While there are 2 distinct examiners involved, all active prosecution is concentrated within 1 distinct art unit. JONGHWAN NMN BAEK is the busiest examiner, managing 1 pending office action. This structure indicates that while the technical subject matter is consistent enough to remain within a single art unit, the USPTO has assigned the cases to different individuals for review, which may lead to different interpretive styles.

The use of 1 distinct art unit for 2 pending office actions suggests a consistent administrative environment. This allows the applicant to apply a unified understanding of art unit policies while tailoring specific technical arguments to the 2 distinct examiners. Since JONGHWAN NMN BAEK and the other examiner each handle 1 pending office action, the workload is evenly distributed. Practitioners should look for commonalities in the 2 pending office actions that might allow for shared research or consistent claim strategies. However, they must remain sensitive to the fact that 2 distinct examiners may reach different conclusions on similar technical points within the Biotechnology & Pharmaceuticals field.